# Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

> **NCT04309773** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 104 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis
- Cholestasis

## Interventions

- **DRUG:** Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
- **DRUG:** Placebo of Bezafibrate in addition to standard UDCA therapy

## Key facts

- **NCT ID:** NCT04309773
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2023-03
- **Final completion:** 2025-03
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309773, "Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04309773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*